Isolation and characterization of a novel pituitary tumor apoptosis gene.

To determine mechanisms for pituitary neoplasia we used methylation-sensitive arbitrarily primed-PCR to isolate novel genes that are differentially methylated relative to normal pituitary. We report the isolation of a novel differentially methylated chromosome 22 CpG island-associated gene (C22orf3). Sodium bisulfite sequencing of pooled tumor cohorts, used in the isolation of this gene, showed that only a proportion of the adenomas within the pools were methylated; however, expression analysis by quantitative RT-PCR of individual adenoma irrespective of subtype showed the majority (30 of 38; 79%) failed to express this gene relative to normal pituitary. Sodium bisulfite sequencing of individual adenomas showed that 6 of 30 (20%) that failed to express pituitary tumor apoptosis gene (PTAG) were methylated; however, genetic change as determined by loss of heterozygosity and sequence analysis was not apparent in the remaining tumors that failed to express this gene. In those cases where the CpG island of these genes was methylated it was invariably associated with loss of transcript expression. Enforced expression of C22orf3 in AtT20 cells had no measurable effects on cell proliferation or viability; however, in response to bromocriptine challenge (10-40 microm) cells expressing this gene showed a significantly augmented apoptotic response as determined by both acridine orange staining and TUNEL labeling. The apoptotic response to bromocriptine challenge was inhibited in coincubation experiments with the general caspase inhibitor z-VAD-fmk. In addition, in time course experiments, direct measurement of active caspases by fluorochrome-labeled inhibition of caspases, showed an augmented increase (approximately 2.4 fold) in active caspases in response to bromocriptine challenge in cells expressing C22orf3 relative to those harboring an empty vector control. The pituitary tumor derivation and its role in apoptosis of this gene led us to assign the acronym PTAG to this gene and its protein product. The ability of cells, showing reduced expression of PTAG, to evade or show a blunted apoptotic response may underlie oncogenic transformation in both the pituitary and other tumor types.

[1]  W. Farrell,et al.  Loss of expression of the growth inhibitory gene GADD45γ, in human pituitary adenomas, is associated with CpG island methylation , 2004, Oncogene.

[2]  D. Danila,et al.  A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. , 2003, The Journal of clinical endocrinology and metabolism.

[3]  J. Trapani,et al.  Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. , 2003, Cancer research.

[4]  S. R. Datta,et al.  Bad-deficient mice develop diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  W. Farrell,et al.  Epigenetic change in pituitary tumorigenesis. , 2003, Endocrine-related cancer.

[6]  D. Labuda,et al.  International Congress on Hormonal Steroids and Hormones and Cancer Prostate cancer susceptibility genes: lessons learned and challenges posed , 2003 .

[7]  B. Gaston,et al.  Nitrosylation of Cytochrome c during Apoptosis* , 2003, The Journal of Biological Chemistry.

[8]  Ming Jiang,et al.  Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. , 2003, Genes & development.

[9]  S. Asa,et al.  The pathogenesis of pituitary tumours , 2002, Nature Reviews Cancer.

[10]  A. Sakurada,et al.  A microarray-based method for detecting methylated loci , 2002, Journal of Human Genetics.

[11]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[12]  D. Danila,et al.  Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. , 2002, The Journal of clinical endocrinology and metabolism.

[13]  W. Farrell,et al.  Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion , 2002, Oncogene.

[14]  C. M. Chen,et al.  Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. , 2001, Cancer research.

[15]  G. Kroemer,et al.  Organelle-specific initiation of cell death pathways , 2001, Nature Cell Biology.

[16]  R. Lloyd,et al.  Molecular pathology of pituitary adenomas , 2001, Journal of Neuro-Oncology.

[17]  R. Fahlbusch,et al.  CDKN2A/p16 inactivation is related to pituitary adenoma type and size , 2001, The Journal of pathology.

[18]  Z. Darżynkiewicz,et al.  Activation of caspases measured in situ by binding of fluorochrome-labeled inhibitors of caspases (FLICA): correlation with DNA fragmentation. , 2000, Experimental cell research.

[19]  K. Fukunaga,et al.  Involvement of p38 Mitogen-Activated Protein Kinase Activation in Bromocriptine-Induced Apoptosis in Rat Pituitary GH3 Cells1 , 2000, Biology of reproduction.

[20]  W. Farrell,et al.  Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. , 2000, Cancer research.

[21]  W. Farrell,et al.  Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line. , 1999, Molecular endocrinology.

[22]  Santoro,et al.  p16 (INK4a, MTS‐1) gene polymorphism and methylation status in human pituitary tumours , 1999, Clinical endocrinology.

[23]  W. Farrell,et al.  Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  T. Kokunai,et al.  Bromocriptine-induced apoptosis in pituitary adenoma cells: relationship to p53 and bcl-2 expression , 1999, Journal of Clinical Neuroscience.

[25]  S. Baylin,et al.  Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. , 1999, Cancer research.

[26]  W. Farrell,et al.  Hypermethylation of the p16/CDKN2A/MTS1 gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas , 1999, Genes, chromosomes & cancer.

[27]  S. Melmed.  Pathogenesis of pituitary tumors. , 1999, Endocrinology and metabolism clinics of North America.

[28]  S. Melmed,et al.  Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. , 1999, The Journal of clinical endocrinology and metabolism.

[29]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[30]  J. Yokota,et al.  Identification of CpG islands hypermethylated in human lung cancer by the arbitrarily primed-PCR method , 1998, Human Genetics.

[31]  T. Sano,et al.  Infrequent mutations of p27Kip1 gene and trisomy 12 in a subset of human pituitary adenomas. , 1997, The Journal of clinical endocrinology and metabolism.

[32]  K. Post,et al.  Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation , 1997, Molecular carcinogenesis.

[33]  S. Melmed,et al.  Isolation and characterization of a pituitary tumor-transforming gene (PTTG). , 1997, Molecular endocrinology.

[34]  S. Korsmeyer,et al.  bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Lubahn,et al.  Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. , 1997, Cancer research.

[36]  R. Thakker,et al.  Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. , 1997, The Journal of clinical endocrinology and metabolism.

[37]  G. Liang,et al.  Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. , 1997, Cancer research.

[38]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Lightman,et al.  p53 gene mutations in pituitary adenomas: rare events , 1994, Clinical endocrinology.

[40]  S. Clark,et al.  High sensitivity mapping of methylated cytosines. , 1994, Nucleic acids research.

[41]  J. Roberts,et al.  c-myc, c-fos, and c-myb gene expression in human pituitary adenomas. , 1994, The Journal of clinical endocrinology and metabolism.

[42]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[43]  S. Cross,et al.  Purification of CpG islands using a methylated DNA binding column , 1994, Nature Genetics.

[44]  D. Yin,et al.  Induction of apoptosis in murine ACTH‐secreting pituitary adenoma cells by bromocriptine , 1994, FEBS letters.

[45]  M. Cusimano,et al.  Pituitary Carcinoma , 1994, Skull base surgery.

[46]  J. Kawai,et al.  Methylation profiles of genomic DNA of mouse developmental brain detected by restriction landmark genomic scanning (RLGS) method. , 1993, Nucleic acids research.

[47]  D. Johnston,et al.  Dopamine regulates D2 receptor gene expression in normal but not in tumorous rat pituitary cells , 1993, Molecular and Cellular Endocrinology.

[48]  A. Arnold,et al.  Clinically nonfunctioning pituitary tumors are monoclonal in origin. , 1990, The Journal of clinical investigation.

[49]  E. Clementi,et al.  A new constitutively activating mutation of the Gs protein alpha subunit-gsp oncogene is found in human pituitary tumours. , 1990, Oncogene.

[50]  H. Bourne,et al.  GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours , 1989, Nature.

[51]  M. Frommer,et al.  CpG islands in vertebrate genomes. , 1987, Journal of molecular biology.

[52]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[53]  B. Scheithauer,et al.  Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas , 2001, Endocrine pathology.

[54]  A. Valentini,et al.  Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). , 1999, Molecular endocrinology.

[55]  J. Herman,et al.  Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.

[56]  D. Yin,et al.  Induction of apoptosis in rat somatotrophin-secreting pituitary adenoma cells by bromocriptine. , 1993, Oncology Research.

[57]  M. Memo,et al.  Epidermal growth factor induces the functional expression of dopamine receptors in the GH3 cell line. , 1991, Endocrinology.